Cargando…

Endocrine determinants of incident sarcopenia in middle-aged and elderly European men

BACKGROUND: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these...

Descripción completa

Detalles Bibliográficos
Autores principales: Gielen, Evelien, O'Neill, Terence W, Pye, Stephen R, Adams, Judith E, Wu, Frederick C, Laurent, Michaël R, Claessens, Frank, Ward, Kate A, Boonen, Steven, Bouillon, Roger, Vanderschueren, Dirk, Verschueren, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575556/
https://www.ncbi.nlm.nih.gov/pubmed/26401471
http://dx.doi.org/10.1002/jcsm.12030
_version_ 1782390793412018176
author Gielen, Evelien
O'Neill, Terence W
Pye, Stephen R
Adams, Judith E
Wu, Frederick C
Laurent, Michaël R
Claessens, Frank
Ward, Kate A
Boonen, Steven
Bouillon, Roger
Vanderschueren, Dirk
Verschueren, Sabine
author_facet Gielen, Evelien
O'Neill, Terence W
Pye, Stephen R
Adams, Judith E
Wu, Frederick C
Laurent, Michaël R
Claessens, Frank
Ward, Kate A
Boonen, Steven
Bouillon, Roger
Vanderschueren, Dirk
Verschueren, Sabine
author_sort Gielen, Evelien
collection PubMed
description BACKGROUND: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these hormones and incident sarcopenia defined as low muscle mass and function. The aim of this study was to determine whether the baseline levels of sex hormones, vitamin D metabolites, and IGF-1 predict changes in muscle mass, muscle strength, physical performance, and incident sarcopenia. METHODS: In 518 men aged 40–79 years, recruited for participation in the European Male Ageing Study, total, free, and bioavailable testosterone (T), oestradiol (E), sex hormone-binding globulin, IGF-1, 25-hydroxyvitamin D (25OHD), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), and parathyroid hormone were assessed at baseline. Appendicular lean mass (aLM), gait speed, and grip strength were measured at baseline and after a mean follow-up of 4.3 years. Sarcopenia was defined by the definition of Baumgartner (relative aLM ≤7.26 kg/m(2)), the International Working Group on Sarcopenia (IWGS), and the European Working Group on Sarcopenia in Older People (EWGSOP). RESULTS: aLM significantly decreased from age 50 years, while gait speed and grip strength significantly decreased from age 70 years. The incidence of sarcopenia by the definitions of Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and 1.6%, respectively. After adjustment for age, centre, body mass index, smoking, and number of comorbidities at baseline, baseline levels of T and vitamin D metabolites were not associated with change in aLM, gait speed, and/or grip strength, while a high baseline level of total E(2) was associated with a greater decrease in aLM. In men aged ≥70 years, low IGF-1 was associated with a greater decrease in gait speed. Baseline endocrine variables were not independently associated with an increased risk of incident sarcopenia by any definition. CONCLUSIONS: Low levels of T and 25OHD do not predict loss of muscle mass, gait speed, or grip strength in middle-aged and elderly community-dwelling European men. Low IGF-1 predicts change in gait speed in men aged ≥70 years.
format Online
Article
Text
id pubmed-4575556
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45755562015-09-23 Endocrine determinants of incident sarcopenia in middle-aged and elderly European men Gielen, Evelien O'Neill, Terence W Pye, Stephen R Adams, Judith E Wu, Frederick C Laurent, Michaël R Claessens, Frank Ward, Kate A Boonen, Steven Bouillon, Roger Vanderschueren, Dirk Verschueren, Sabine J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these hormones and incident sarcopenia defined as low muscle mass and function. The aim of this study was to determine whether the baseline levels of sex hormones, vitamin D metabolites, and IGF-1 predict changes in muscle mass, muscle strength, physical performance, and incident sarcopenia. METHODS: In 518 men aged 40–79 years, recruited for participation in the European Male Ageing Study, total, free, and bioavailable testosterone (T), oestradiol (E), sex hormone-binding globulin, IGF-1, 25-hydroxyvitamin D (25OHD), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), and parathyroid hormone were assessed at baseline. Appendicular lean mass (aLM), gait speed, and grip strength were measured at baseline and after a mean follow-up of 4.3 years. Sarcopenia was defined by the definition of Baumgartner (relative aLM ≤7.26 kg/m(2)), the International Working Group on Sarcopenia (IWGS), and the European Working Group on Sarcopenia in Older People (EWGSOP). RESULTS: aLM significantly decreased from age 50 years, while gait speed and grip strength significantly decreased from age 70 years. The incidence of sarcopenia by the definitions of Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and 1.6%, respectively. After adjustment for age, centre, body mass index, smoking, and number of comorbidities at baseline, baseline levels of T and vitamin D metabolites were not associated with change in aLM, gait speed, and/or grip strength, while a high baseline level of total E(2) was associated with a greater decrease in aLM. In men aged ≥70 years, low IGF-1 was associated with a greater decrease in gait speed. Baseline endocrine variables were not independently associated with an increased risk of incident sarcopenia by any definition. CONCLUSIONS: Low levels of T and 25OHD do not predict loss of muscle mass, gait speed, or grip strength in middle-aged and elderly community-dwelling European men. Low IGF-1 predicts change in gait speed in men aged ≥70 years. John Wiley & Sons, Ltd 2015-09 2015-04-27 /pmc/articles/PMC4575556/ /pubmed/26401471 http://dx.doi.org/10.1002/jcsm.12030 Text en © 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Gielen, Evelien
O'Neill, Terence W
Pye, Stephen R
Adams, Judith E
Wu, Frederick C
Laurent, Michaël R
Claessens, Frank
Ward, Kate A
Boonen, Steven
Bouillon, Roger
Vanderschueren, Dirk
Verschueren, Sabine
Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
title Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
title_full Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
title_fullStr Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
title_full_unstemmed Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
title_short Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
title_sort endocrine determinants of incident sarcopenia in middle-aged and elderly european men
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575556/
https://www.ncbi.nlm.nih.gov/pubmed/26401471
http://dx.doi.org/10.1002/jcsm.12030
work_keys_str_mv AT gielenevelien endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT oneillterencew endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT pyestephenr endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT adamsjudithe endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT wufrederickc endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT laurentmichaelr endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT claessensfrank endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT wardkatea endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT boonensteven endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT bouillonroger endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT vanderschuerendirk endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen
AT verschuerensabine endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen